Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects

January 15, 2015 updated by: Solvay Pharmaceuticals

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Female Subjects With Recent Onset Atrial Fibrillation

The purpose of this study is to demonstrate the ability of tedisamil to convert atrial fibrillation or flutter into normal sinus rhythm (NSR) in female patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
      • Buenos Aires, Argentina
        • Site 2
      • Buenos Aires, Argentina
        • Site 3
      • Munro, Argentina
        • Site 5
      • Tucuman, Argentina
        • Site 4
  • Czech Republic
      • Brno, Czech Republic
        • Site 8
      • Jindrichuv Hradec, Czech Republic
        • Site 11
      • Ostrava-Poruba, Czech Republic
        • Site 9
      • Plzen, Czech Republic
        • Site 10
      • Prague, Czech Republic
        • Site 14
      • Prague, Czech Republic
        • Site 6
      • Prague, Czech Republic
        • Site 7
      • Slany, Czech Republic
        • Site 12
      • Usti nad Orlici, Czech Republic
        • Site 13
  • Former Serbia and Montenegro
      • Belgrade, Former Serbia and Montenegro
        • Site 52
      • Belgrade, Former Serbia and Montenegro
        • Site 53
      • Belgrade, Former Serbia and Montenegro
        • Site 54
      • Belgrade, Former Serbia and Montenegro
        • Site 57
      • Belgrade, Former Serbia and Montenegro
        • Site 58
      • Niska Banja, Former Serbia and Montenegro
        • Site 56
      • Sremska Kamenica, Former Serbia and Montenegro
        • Site 55
  • Germany
      • Bad Nauheim, Germany
        • Site 15
      • Gottingen, Germany
        • Site 17
      • Halle, Germany
        • Site 16
  • Israel
      • Haifa, Israel
        • Site 18
      • Jerusalem, Israel
        • Site 19
      • Jerusalem, Israel
        • Site 22
      • Jerusalem, Israel
        • Site 23
      • Tel-Aviv, Israel
        • Site 20
      • Tel-Aviv, Israel
        • Site 21
  • Poland
      • Bydgoszcz, Poland
        • Site 26
      • Bydgoszcz, Poland
        • Site 32
      • Lodz, Poland
        • Site 30
      • Lublin, Poland
        • Site 29
      • Lublin, Poland
        • Site 36
      • Medyczna, Poland
        • Site 31
      • Szczecin, Poland
        • Site 33
      • Warszawa, Poland
        • Site 24
      • Warszawa, Poland
        • Site 25
      • Warszawa, Poland
        • Site 27
      • Warszawa, Poland
        • Site 28
      • Wroclaw, Poland
        • Site 34
      • Wroclaw, Poland
        • Site 35
  • Romania
      • Brasov, Romania
        • Site 38
      • Bucharest, Romania
        • Site 40
      • Bucharest, Romania
        • Site 39
      • Tg. Mures, Romania
        • Site 37
  • Russian Federation
      • Moscow, Russian Federation
        • Site 51
      • Moscow, Russian Federation
        • Site 41
      • Moscow, Russian Federation
        • Site 42
      • Moscow, Russian Federation
        • Site 43
      • Moscow, Russian Federation
        • Site 44
      • Moscow, Russian Federation
        • Site 45
      • Moscow, Russian Federation
        • Site 46
      • Moscow, Russian Federation
        • Site 47
      • Moscow, Russian Federation
        • Site 48
      • Moscow, Russian Federation
        • Site 49
      • St. Petersburg, Russian Federation
        • Site 50
  • Slovakia
      • Banska Bystrica, Slovakia
        • Site 60
      • Bratislava, Slovakia
        • Site 64
      • Kosice, Slovakia
        • Site 61
      • Lucenec, Slovakia
        • Site 62
      • Nitra, Slovakia
        • Site 59
      • Nove Zamky, Slovakia
        • Site 65
      • Presov, Slovakia
        • Site 63
  • South Africa
      • Cape Town, South Africa
        • Site 66
      • Cape Town, South Africa
        • Site 67
  • Ukraine
      • Dnepropetrovsk, Ukraine
        • Site 68
      • Dnepropetrovsk, Ukraine
        • Site 69
      • Donetsk, Ukraine
        • Site 71
      • Donetsk, Ukraine
        • Site 72
      • Kharkiv, Ukraine
        • Site 75
      • Kiev, Ukraine
        • Site 70
      • Kiev, Ukraine
        • Site 73
      • Kiev, Ukraine
        • Site 76
      • Kiev, Ukraine
        • Site 77
      • Lviv, Ukraine
        • Site 74
      • Odessa, Ukraine
        • Site 80
      • Zaporizhya, Ukraine
        • Site 79
      • Zaporozhye, Ukraine
        • Site 78
  • United Kingdom
      • London, United Kingdom
        • Site 81
  • United States
    • Tennessee
      • Tullahoma, Tennessee, United States
        • Site 82

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Willing to sign informed consent before screening examinations are performed and before the study drug is administered
  • Females > 18 years of age
  • Subjects with documented (60 second rhythm strip) symptomatic atrial fibrillation or flutter (duration > 3 hours and < 45 days) at the time of randomization
  • Subjects who are in no distress and hemodynamically stable (supine systolic blood pressure > 90 mmHg and diastolic blood pressure < 105 mmHg)

Exclusion Criteria:

  • Pregnancy and lactation
  • Acute myocardial infarction and cerebrovascular accidents
  • Coronary syndromes and congestive heart failure (CHF) New York Heart Association (NYHA) IV
  • Life-threatening ventricular arrhythmias and electrocardiogram (ECG) abnormalities
  • Concurrent antiarrhythmic treatments

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Solvay Pharmaceuticals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2004

Primary Completion (Actual)

March 1, 2006

Study Completion (Actual)

March 1, 2006

Study Registration Dates

First Submitted

August 1, 2005

First Submitted That Met QC Criteria

August 1, 2005

First Posted (Estimate)

August 2, 2005

Study Record Updates

Last Update Posted (Estimate)

January 16, 2015

Last Update Submitted That Met QC Criteria

January 15, 2015

Last Verified

March 1, 2006

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • S219.3.116
  • 2004-000460-27

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Atrial Fibrillation

Clinical Trials on Tedisamil sesquifumarate

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe